Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Xenon Pharmaceuticals Inc. (XENE) ownership amendment reports that T. Rowe Price Investment Management, Inc. reported 9,996,124 common shares, or 10.3% of the class, as beneficially owned. It reported sole voting power over 9,567,544 shares and sole dispositive power over 9,996,124 shares, with no shared voting or dispositive power. The manager stated that the report is not an admission of beneficial ownership and expressly denied beneficial ownership.
Xenon Pharmaceuticals Inc. (XENE) common stock is the subject of an ownership report by T. Rowe Price Investment Management, Inc., which reported beneficial ownership of 7,905,757 shares, or 8.2% of the class. It reported sole voting power over 7,558,551 shares and sole dispositive power over 7,905,757 shares, with no shared voting or dispositive power. The reporting entity stated that the report is not an admission of beneficial ownership and expressly denied being the beneficial owner of the securities. Ellen York, Vice President, signed for the reporting entity.
Xenon Pharmaceuticals Inc. (XENE) is the issuer whose common stock is covered by an amended beneficial-ownership report from FMR LLC and Abigail P. Johnson. Each reported beneficial ownership of 11,136,649 shares, or 11.5% of the class. FMR LLC reported sole voting power over 11,128,597 shares and sole dispositive power over 11,136,649 shares; Abigail P. Johnson reported no voting power and sole dispositive power over 11,136,649 shares.
The report states that one or more other persons are known to have rights to dividends or sale proceeds from the stock, but no other person's interest exceeds 5% of the outstanding common stock.
Xenon Pharmaceuticals Inc. Chief Financial Officer Thomas Patrick Kelly acquired 7,500 common shares when 7,500 restricted share units vested on October 15, 2026. The award was granted October 15, 2025, and vests 25% on each of the first four anniversaries, beginning October 15, 2026. Kelly directly held 22,500 common shares following the transaction. No Rule 10b5-1 plan is reported.
Xenon Pharmaceuticals Inc. (XENE) Chief Financial Officer Thomas Patrick Kelly purchased 15,000 Common Shares at $37.316 per share on September 30, 2026. The transaction was reported as a direct purchase, and his reported holdings afterward were 15,000 Common Shares. That post-transaction figure is his reported resulting position. No Rule 10b5-1 plan is reported.
Xenon Pharmaceuticals Inc. (XENE) President & CEO Ian Mortimer purchased 30,000 common shares at $37.38 per share on September 30, 2026. After the purchase, he reported 49,923 common shares held directly. A separate holding entry lists 14,300 common shares held indirectly by his spouse.
Xenon Pharmaceuticals Inc. (XENE) director Dawn Svoronos exercised stock options for 5,144 Common Shares on September 1, 2026 at an exercise price of $8.15 per share, converting fully vested options into shares. Following the exercise, she holds 31,373 Common Shares directly, and no related Rule 10b5-1 trading plan is reported.
Xenon Pharmaceuticals Inc. (XENE) reported that Chief Medical Officer Christopher John Kenney sold a total of 7,068 Common Shares on August 28, 2026 in two open-market transactions, executed under a Rule 10b5-1 trading plan adopted on May 29, 2026. The reported prices are weighted-average prices for multiple trades within specified intraday ranges.
Xenon Pharmaceuticals Inc. (XENE) had an officer, Christopher Kenney, file a notice of proposed sale of company stock under Rule 144. The notice covers up to 7,068 common shares, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $437,721.24 and listing on NASDAQ. The shares are to be sold on or after 08/28/2026 and were acquired upon vesting of restricted and performance stock units from Xenon on 03/09/2026 and 03/12/2026.
Xenon Pharmaceuticals Inc. director Steven Gannon reported selling 10,000 Common Shares on August 11, 2026 in an open market or private transaction. The shares were sold at a weighted-average price of $64.055 across multiple trades priced between $64.0517 and $64.078 per share. Following this sale, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.